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Abstract. Many pharmaceuticals currently available
were discovered either during the screening of natural
of synthetic product libraries or by serendipitous ob-
servation. Such a “random” approach entails testing
numerous compounds and developing countless high-
throughput screening assays. On the other hand, a “ra-
tional” approach involves the structure-based route to
drug discovery, where the structure of a target protein is
determined. Hypothetical ligands may be predicted by
molecular modelling, while movement of a molecule may
be predicted by Molecular Dynamics Simulations prior
to synthetic chemical synthesis of a particular molecule.
Here, we will be discussing protein structure-based ap-
proaches to drug discovery.
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1 Introduction
Proteins are complex molecules composed of long strings
of twenty different types of amino acid. The length of
the string and the order of amino acids are vitally im-
portant for the protein to function properly in its biolo-
gical role. This part of the process of protein function,
the gene encoding the protein determines these factors.
A single mistake (mutation) in the gene may cause the
wrong amino acid to be incorporated into the sequence
or a nonsense mutation may cause the protein to be
truncated. However, protein function is more directly
determined by the protein’s three dimensional shape,
the protein structure, and the availability of non-protein
cofactors.
2 Protein Structure - why is it import-
ant?
As can be seen in Fig. 1, a complex protein such as
xanthine oxidoreductase (XOR) forms a highly convo-
luted structure, but one which accommodates cofactors
and substrates perfectly. Protein structure is typically
determined by one of three methods today; X-Ray crys-
tallography, Nuclear Magnetic Resonance spectroscopy
(NMR) or cryoelectron microscopy. The former is the
oldest and most commonly used technique, while the lat-
ter is only just becoming available for the analysis of pro-
teins at atomic resolution. X-Ray crystallography relies
on the ability of the protein to form a regular molecular
array and crystallise; a completely biologically unnat-
ural condition for any protein. Even so, it is possible and
there are now over one hundred thousand entries in the
biological structures databank, RCSB (Deshpande et
al., 2005). The advantage of NMR over X-Ray crystallo-
graphy is that it can be performed in solution (no crys-
tals required) but the major problem is size; NMR can-
not be used to determine the structure of large proteins.
Electron microscopy will soon be capable of providing
structural information about protein as good as X-Ray
crystallography, and is performed in solution. Today
it can yield protein structures to 2.2 A˚ (X-Rays typic-
ally give resolutions as high as 0.6 to 1.3 A˚). In the
laboratory of Biochemistry and Protein Science, at the
University of Malta, we use X-Ray crystallography to
determine protein structure, with crystallisation condi-
tions determined in our laboratory applied and subjec-
ted to X-Ray diffraction at the University of Leeds, UK
in collaboration with Dr Chi Trinh. We have determ-
ined the structures of several superoxide dismutase en-
zymes and mutants (to a minimum of 1.7 A˚) and are
currently working to solve the structures of others, in-
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Figure 1: Bovine Xanthine Oxidoreductase. Only one of two identical protein subunits is shown, in cartoon representation with
blue beta sheets (arrows) and cream alpha helices (spirals). Cofactors and substrates are shown surrounding the protein in ball-and-
stick representation and their corresponding positions of binding within the protein as atomic spheres. NAD is in orange, FAD is in
yellow, iron-sulphur clusters are brown, the molybdopterin is purple and xanthine (substrate) in green. Together, the protein forms a
scaffold for the cofactors which form an electron transport chain from one side of the protein (substrate) to the other (FAD/NAD).
The figure was created using the PyMOL molecular Graphics System (Schro¨dinger LLC, 2010).
cluding human XOR. Structures such as these help us to
understand how the protein functions, and will help to
design chemicals to be used pharmaceutically as modifi-
ers of enzyme activity. X-Ray structures usually provide
us with a quite static picture of the protein, and it is
best combined with other techniques in order to obtain
a detailed idea of how the protein functions.
3 Molecular Dynamics Simulations of
Biomolecules
Molecular Dynamics Simulations are applied in the in-
vestigation of numerous dynamic properties and pro-
cesses by scientists in a variety of fields that in-
clude structural biochemistry, enzymology, biophys-
ics, molecular biology, biotechnology and pharmaceut-
ical chemistry. Molecular Dynamics Simulations allow
the researcher to study the thermodynamic and time-
dependent (kinetic) properties of biomolecules such as
proteins. This provides an understanding of numerous
dynamic aspects of biomolecular structure, recognition,
and function (Adcock & McCammon, 2006) The tech-
niques involving Molecular Dynamics Simulations in-
volve Langevin’s or Newton’s equations of motion, as
well as a particular molecular bond structure, paramet-
rized force fields, and an initial conformation of atomic
positions, together with the velocities that are neces-
sary to generate the atomic dynamics in a molecular
system. Molecular Dynamics Simulations have a lim-
ited function when used in isolation. The trajectory of
Molecular Dynamics (i.e., the progress of a simulated
structure correlated to time) usually generates data re-
lated only to the level of atomic positions, velocities
and single-point energies. Researchers are usually inter-
ested in obtaining macroscopic properties. The latter
requires the application of statistical mechanics, which
combines microscopic simulations together with macro-
scopic observables. Statistical mechanics provide the
mathematical expressions associating the distributions
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and motions of atoms to macroscopic observables in-
cluding free energy, pressure and heat capacity (Callen,
1985; McQuarrie, Salvaterra, De Blas, Routes & Mahler,
1976). Molecular Dynamics Simulation programs in-
clude AMBER, CHARMM, NAMD and POLY-MD.
Kinetic rate constants of ligand-receptor interactions
are essential in enzymology (Bar-Even et al., 2011) and
drug discovery (Copeland, Pompliano & Meek, 2006), as
they provide a good indication of drug efficacy (Cope-
land et al., 2006). Thus, the prediction and optimisa-
tion of these parameters is an important challenge in
medicinal chemistry (Copeland, 2016). Even though
these values may be measured experimentally, an accur-
ate computational prediction would result in a useful
alternative in cases where the experiment is either ex-
pensive or difficult to perform. Additionally, advances
in computational power, have allowed simulations to be
carried out in significantly less time. This provides a
great potential for methods that require vast amounts
of computational power.
Predicting the interaction between an enzyme and
its substrate and other ligands via Molecular Dynamics
Simulations is essential to fully understand the mech-
anism of the enzyme. Predicting hydrogen bonding in
an enzyme is crucial for analysing the structure and
function of this type of biological molecule, especially in
terms of enzyme catalysis. Molecular Dynamics Simula-
tions provide information on the molecule that is not ob-
servable in the data obtained via X-ray crystallography
experiments alone. With this knowledge it is then pos-
sible to design new chemicals based upon the binding
requirements discovered to inhibit or enhance the bio-
logical activity of the protein. In many cases it may
be adventitious to modify the structure of an existing,
known effector molecule (enhancer or inhibitor) to in-
crease or decrease its activity. With computer aided
rational design, a new or modified pharmaceutical may
be created with better effectiveness and reduced side ef-
fects. Molecular simulations give us the power to suggest
or reject such modifications prior to chemical synthesis
of the compound. This saves time, effort and money.
4 Protein Structure, Molecular Dynam-
ics, Drug Discovery - tying the knot
with computational approaches
Structure-based virtual screening is a computational
method employed to find small, bioactive molecules
which sterically fit and interact with a protein. A lib-
rary of small molecules (ligands) is “docked” to the pro-
tein’s binding site in a typical “lock-and-key” fashion
(Meng, Zhang, Mezei & Cui, 2011). Three things are re-
quired for this computational approach. Firstly, a pro-
tein structure is either determined experimentally (as
described earlier) or modelled computationally, typic-
ally using homology modelling. In homology modelling,
we use one or more known protein structures with close
sequence similarity as a template to model our protein
of interest. The binding site on the protein needs to be
identified. Secondly, a library of small molecules must
be prepared and provided to the docking algorithm.
This preparation may imply many steps such as sanit-
isation, setting the appropriate ionization state, remov-
ing salts, etc. Thousands to millions of molecules form
part of the digital library, only a fraction of which could
possibly be tested physically in a laboratory. Thirdly,
a docking protocol is required which defines the para-
meters used in the docking experiment. This includes,
but is not limited to, ligand flexibility, protein side-chain
flexibility, role of water molecule in the binding site, and
which scoring function to use. The scoring function is
of critical importance as it assesses the goodness of the
fit, producing a quantitative score which can be used
to rank each individual ligand. Many aspects are taken
into consideration when evaluating the interaction of the
protein with each ligand including steric fit, electrostat-
ics, polar interactions and hydrogen bonding. The prob-
lem is compounded by the many possible conformations
the ligand (or protein) takes on. The scoring function
must evaluate each of these binding poses. Some of the
major critiques of docking are the inability to calculate
the free binding energy correctly (possibly because of
the additive nature of most scoring functions), protein
main-chain flexibility, the correct prediction of water in
binding and the intensive computational resources re-
quired. In order to alleviate some of these issues, dock-
ing is sometimes used as a filtering first step before a
more rigorous and computationally intensive molecular
dynamics simulation. The top hits of the docking exper-
iment are then rescored using MD. In a typical workflow,
large virtual screening databases are first filtered using
fast and inexpensive docking protocols. This rescoring is
based on more physically realistic techniques for binding
free energy estimations such as thermodynamic integra-
tion, free energy perturbation, linear interaction energy
and molecular mechanics/Poisson-Boltzmann and sur-
face area (MM/PB-SA). Overall, this provides a more
accurate prediction of the binding affinity between the
protein and the ligand (compared to the scoring func-
tion in docking tools). Computer-aided drug design is
an active field of research, which has gained a lot of
momentum in recent years - mostly driven by the de-
creasing productivity of the pharmaceutical industry to
find new drugs.
5 Limitations of MD-based methods
The main force fields that are currently being employed
for biomolecular simulations include AMBER (Asensio
& Jimenez-Barbero, 1995), CHARMM (MacKerell et
10.7423/XJENZA.2016.2.03 www.xjenza.org
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Figure 2: Components of a computational protein-ligand docking experiment. The goodness-of-fit of different small-
molecules in a protein’s pocket is assessed by means of a scoring function. The top-ranked results may serve as input to more
computationally exhaustive techniques, such as Molecular Dynamics.
al., 1998), and OPLS (Jorgensen & Tirado-Rives, 1988).
Although, extended parametrisation for amino acids,
nucleic acids, lipids, carbohydrates, and several ionic
species has been included in the parent force fields in
recent years, the variability of small molecules (i.e., lig-
ands) still poses a challenge to condensed-phase force
fields. Thus, the user must carry out specific paramet-
risation. The latter is a time-consuming and an error-
prone procedure, and has lead to the development of
some general force field sets such as GAFF57 for AM-
BER, and CGenFF58 for CHARMM, together with spe-
cific parametrisation toolkits. Several challenges must
be overcome to further increase the importance of MD-
based methods on drug design. The molecular mechan-
ics force fields that are presently available partially or
fully neglect charge transfer and polarisation effects, as
well as many electronic-based interactions. The current
limits of force field and MD-based methods allow certain
10.7423/XJENZA.2016.2.03 www.xjenza.org
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target families, such as metalloproteins, to be studied
with limited accuracy (De Vivo, Masetti, Bottegoni &
Cavalli, 2016).
6 Conclusion
It is the combination of computational approaches that
encompass techniques such as molecular dynamics sim-
ulations and docking, together with the interpretation
of related experimental structural data, which is essen-
tial to provide a comprehensive understanding of the
motions in proteins and their assemblies. Information
on the latter is crucial when synthesising improved bio-
molecules and designing new drugs.
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